Sandbox Reserved 1096

From Proteopedia

Revision as of 15:58, 12 January 2020 by Emma Tixier (Talk | contribs)
Jump to: navigation, search
This Sandbox is Reserved from 25/11/2019, through 30/9/2020 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1091 through Sandbox Reserved 1115.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Contents

Human Peptidylarginine Deiminase Type 2

General Description

Insert caption here

Drag the structure with the mouse to rotate

Protein Arginine Deiminase type 2 also known as PAD2, is a calcium-dependent enzyme that catalyzes in humans the conversion of Arginine residues into Citrulline in a post-translational modification referred to as Citrullination. The structure of PAD2 Apoenzyme described here was elucidated at a calcium concentration of 0mM (Ca2+) with a resolution of 1.657 Å by x-ray diffraction cristallography[1] . The biological assembly of PAD2 consists of a head-to-tail dimer with immunoglobin-like domains and a nucleophilic cysteine residue responsible of catalytic activity in the active site [2]. In humans, five genes clustered in a single locus code for Arginine deiminases: PADI1,PADI2,PADI3,PADI4,PADI6[3]. Expression of different isoforms of PAD seem to depend strongly on cell types and tissues even though PAD2 may be an ubiquist protein [3]. Peptidyl Arginine Deiminase type 2 appears to have an essential role in the development of Breast Cancer [2], Multiple Sclerosis(MS)[4] and other degenerative disorders such as Rheumatoid Arthritis [3] thus making it a potential target for inhibitor design treatments. Related structures for PAD2 include: 4n2b and 4n2c.

Structural Features

Primary, secondary and tertiary structure

Calcium binding sites and active site

The structure of the apoenzyme apoPAD2 shows a stable head to tail dimer.The monomer is formed by 2 immunoglobulin-like domains and a C-term catalytic domain calcium binding site. There are six different calcium binding sites C1 to C6 C2-5 are unoccupied in apoPAD2 but there is an electron density on C1 and C6 so those are occupied by calcium[5], for instance around 20% of isolated MBP is citrullinated in normal human adults whereas an average of 45% citrullinated MBP was detected in chronic MS patients and up to 80% for fulminating MS (Marburg's Syndrome)[6][7]. Given that hyper-citrullination of MBP marks important stages in the development of the CNS, MBP's citrullination by PAD2 in MS patients suggests a switch to immaturity as a repair mechanism for neurological damage[4]. This switch to immaturity could however promote or initiate pathological effects in MS.

Numerous post-translational modifications in myelin sheath-related proteins can alter folding and 3D configuration of polypeptides thus modifying functional and structural properties of the tissue [8]. These modifications may naturally occur as regulatory processes in cells but, in the case of MBP's citrullination, they may promote/initiate pathological states[4]. Two main consequences regarding Myelin Basic Protein citrullinaton have been proposed: 1) Change of arginine residues to citrulline by PADs could trigger the generation of neo-epitopes for which no tolerance exists; 2) Citrullination may induce MBP's misfolding exposing immunodominant epitopes[4]. Both effects result in auto-immune responses towards CNS tissues in the first case due to the newly generated neo-epitopes that trigger 'new' immunological responses. In the second case, pertubation of internal electrostatic interations within MBP as a consequence of citrullination may generate misfolded versions of the protein in the myelin sheath that were proven to be more extended[9]. These newly generated versions of MBP enhance the exposure of a central-membrane-binding fragment that represents a primary immunodominant epitope in the cytoplasm and is thus its proteolysis is capable of generating more immunodominant species that trigger immunological responses[10][11]. Modification of MBP's functional properties may have a direct impact in adhesion and compaction of the myelin sheath promoting demyelination in Multiple Sclerosis. Related structures of immunological associations with Myelin Basic Protein have been studied in: 1k2d and 1bx2.

PAD2 and ER Target-gene Expression in Breast Cancer

PAD2 functions as an Estrogen Receptor (ER) coactivator in Breast cancer cells, using the citrullination of histone tail arginine residues at ER binding sites.[12]

Personal tools